Literature DB >> 22854136

Characterization of patients with heterozygous cystinuria.

Mohamed A Elkoushy1, Sero Andonian.   

Abstract

OBJECTIVE: To characterize a contemporary cohort of patients with heterozygous (TZ) cystinuria and compare them with a concurrent cohort of patients with homozygous (MZ) cystinuria.
METHODS: A retrospective review of prospectively collected data was performed for 42 consecutive patients presenting with a positive cyanide-nitroprusside test from September 2009 to September 2011. Clinical data were collected, including the findings from a detailed metabolic stone workup that included two 24-hour urine collections with quantitative cystine. The patients were divided into 2 groups: those with TZ (30-400 mg/d) and those with MZ (>400 mg/d) cystinuria.
RESULTS: One patient was excluded because the cystine excretion was within the normal range (<30 mg/d), 35 (83.3%) and 6 (14.3%) had TZ and MZ cystinuria, respectively. Compared with those with TZ cystinuria, those with MZ cystinuria were significantly younger at the first stone episode (median 48 years, range 14-67, vs 17, range 6-44, P = .002), more were female (20% vs 66.7%; P = .03), and more patients had bilateral stones (8.6% vs 50%; P = .03). Finally, the patients with MZ cystinuria had more stone episodes than those with TZ cystinuria (3 vs 1; P = .04). From the detailed metabolic stone evaluation, the incidence of hyperuricemia was significantly greater in the MZ patients (17.1% vs 66.7%; P = .02). Although all the MZ patients developed pure cystine stones, 18 (51.4%), 7 (20.0%), and 3 (8.6%) of the TZ patients developed calcium oxalate, uric acid, and cystine stones, respectively (P < .001). In the TZ group, 11 patients (31.4%) had false-negative results on subsequent cyanide-nitroprusside testing.
CONCLUSION: Significant differences were found between the patients with TZ and MZ cystinuria in terms of age at the first stone episode, male/female ratio, incidence of hyperuricemia, and stone composition. The clinical significance remains to be elucidated.
Copyright © 2012 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22854136     DOI: 10.1016/j.urology.2012.04.062

Source DB:  PubMed          Journal:  Urology        ISSN: 0090-4295            Impact factor:   2.649


  4 in total

Review 1.  Epidemiology of stone disease across the world.

Authors:  Igor Sorokin; Charalampos Mamoulakis; Katsuhito Miyazawa; Allen Rodgers; Jamsheer Talati; Yair Lotan
Journal:  World J Urol       Date:  2017-02-17       Impact factor: 4.226

2.  Cystinuria in a patient with 19q12q13.1 deletion.

Authors:  Teresa de Rojas; Cristina Aparicio; Carmen de Lucas; Beatriz Martinez; Belén Gil-Fournier; Soraya Ramiro-León
Journal:  CEN Case Rep       Date:  2015-09-19

3.  Fourteen monogenic genes account for 15% of nephrolithiasis/nephrocalcinosis.

Authors:  Jan Halbritter; Michelle Baum; Ann Marie Hynes; Sarah J Rice; David T Thwaites; Zoran S Gucev; Brittany Fisher; Leslie Spaneas; Jonathan D Porath; Daniela A Braun; Ari J Wassner; Caleb P Nelson; Velibor Tasic; John A Sayer; Friedhelm Hildebrandt
Journal:  J Am Soc Nephrol       Date:  2014-10-08       Impact factor: 10.121

4.  The Long-Term Follow-Up of Patients with Cystine Stones: A Single-Center Experience for 13 Years.

Authors:  Toshifumi Takahashi; Shinya Somiya; Katsuhiro Ito; Toru Kanno; Yoshihito Higashi; Hitoshi Yamada
Journal:  J Clin Med       Date:  2021-03-24       Impact factor: 4.241

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.